Log In
BCIQ
Print this Print this
 

icaritin (SNG-162)

  Manage Alerts
Collapse Summary General Information
Company Shenogen Pharma Group Ltd.
DescriptionSmall molecule derived from a Chinese herb targeting estrogen receptor alpha 36
Molecular Target Estrogen receptor alpha 36
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationLiver cancer
Indication DetailsTreat hepatocellular carcinoma (HCC)
Regulatory Designation
PartnerLee's Pharmaceutical Holdings Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/24/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today